Literature DB >> 19415920

Identification of natural MHC class II presented phosphopeptides and tumor-derived MHC class I phospholigands.

Verena S Meyer1, Oliver Drews, Marc Günder, Jörg Hennenlotter, Hans-Georg Rammensee, Stefan Stevanovic.   

Abstract

MHC molecules present protein-derived peptides to T lymphocytes. By developing TiO2-based microcentrifugation columns, we identified the first phosphorylated MHC class I ligands from tumor tissue (renal cell carcinoma) and, by comparison to healthy renal tissue, found one Brf1-derived ligand as potentially tumor-associated. We further discovered the first natural phosphorylated MHC class II ligands. They revealed several novel phosphorylation sites of significant transmembrane receptors, such as Frizzled 6, CXCR4 and CD20.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19415920     DOI: 10.1021/pr800937k

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  23 in total

1.  Increased diversity of the HLA-B40 ligandome by the presentation of peptides phosphorylated at their main anchor residue.

Authors:  Miguel Marcilla; Adán Alpízar; Manuel Lombardía; Antonio Ramos-Fernandez; Manuel Ramos; Juan Pablo Albar
Journal:  Mol Cell Proteomics       Date:  2013-12-23       Impact factor: 5.911

Review 2.  Mapping the tumour human leukocyte antigen (HLA) ligandome by mass spectrometry.

Authors:  Lena Katharina Freudenmann; Ana Marcu; Stefan Stevanović
Journal:  Immunology       Date:  2018-05-08       Impact factor: 7.397

Review 3.  Post-translationally modified T cell epitopes: immune recognition and immunotherapy.

Authors:  Jan Petersen; Anthony W Purcell; Jamie Rossjohn
Journal:  J Mol Med (Berl)       Date:  2009-09-08       Impact factor: 4.599

Review 4.  Insights into MHC class I antigen processing gained from large-scale analysis of class I ligands.

Authors:  Gabor Mester; Vanessa Hoffmann; Stefan Stevanović
Journal:  Cell Mol Life Sci       Date:  2011-03-09       Impact factor: 9.261

5.  The human leukocyte antigen-presented ligandome of B lymphocytes.

Authors:  Chopie Hassan; Michel G D Kester; Arnoud H de Ru; Pleun Hombrink; Jan Wouter Drijfhout; Harm Nijveen; Jack A M Leunissen; Mirjam H M Heemskerk; J H Frederik Falkenburg; Peter A van Veelen
Journal:  Mol Cell Proteomics       Date:  2013-03-12       Impact factor: 5.911

6.  A Molecular Basis for the Presentation of Phosphorylated Peptides by HLA-B Antigens.

Authors:  Adán Alpízar; Fabio Marino; Antonio Ramos-Fernández; Manuel Lombardía; Anita Jeko; Florencio Pazos; Alberto Paradela; César Santiago; Albert J R Heck; Miguel Marcilla
Journal:  Mol Cell Proteomics       Date:  2016-12-05       Impact factor: 5.911

7.  Expanding the detectable HLA peptide repertoire using electron-transfer/higher-energy collision dissociation (EThcD).

Authors:  Geert P M Mommen; Christian K Frese; Hugo D Meiring; Jacqueline van Gaans-van den Brink; Ad P J M de Jong; Cécile A C M van Els; Albert J R Heck
Journal:  Proc Natl Acad Sci U S A       Date:  2014-03-10       Impact factor: 11.205

Review 8.  Identifying and Targeting Human Tumor Antigens for T Cell-Based Immunotherapy of Solid Tumors.

Authors:  Vid Leko; Steven A Rosenberg
Journal:  Cancer Cell       Date:  2020-08-20       Impact factor: 31.743

9.  Mass Spectrometry Based Immunopeptidomics Leads to Robust Predictions of Phosphorylated HLA Class I Ligands.

Authors:  Marthe Solleder; Philippe Guillaume; Julien Racle; Justine Michaux; Hui-Song Pak; Markus Müller; George Coukos; Michal Bassani-Sternberg; David Gfeller
Journal:  Mol Cell Proteomics       Date:  2019-12-17       Impact factor: 5.911

10.  Inflammation-Induced Abnormal Expression of Self-molecules on Epithelial Cells: Targets for Tumor Immunoprevention.

Authors:  Camille Jacqueline; Amanda Lee; Nolan Frey; Jonathan S Minden; Olivera J Finn
Journal:  Cancer Immunol Res       Date:  2020-05-28       Impact factor: 11.151

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.